ALXO:NSD-Alx Oncology Holdings  (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 12.79

Change

+1.02 (+8.67)%

Market Cap

USD 0.49B

Volume

0.20M

Avg Analyst Target

USD 38.33 (+199.71%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALXO Stock Forecast & Price:
Based on the Alx Oncology Holdings  stock forecasts from 5 analysts, the average analyst target price for Alx Oncology Holdings  is USD 38.33 over the next 12 months. Alx Oncology Holdings ’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alx Oncology Holdings  is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Alx Oncology Holdings ’s stock price was USD 12.79. Alx Oncology Holdings ’s stock price has changed by +25.52% over the past week, +31.18% over the past month and -80.32% over the last year.

About Alx Oncology Holdings  (ALXO:NSD)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syn ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-3.06 (-1.02%)

USD75.25B 29.60 15.72
MRNA Moderna Inc

+3.13 (+1.83%)

USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

+19.34 (+3.11%)

USD67.87B 12.49 9.34
BNTX BioNTech SE

+3.71 (+2.36%)

USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.05 (+0.03%)

USD32.39B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.25 (+0.57%)

USD29.52B 42.40 20.35
ALNY Alnylam Pharmaceuticals Inc

+8.63 (+3.86%)

USD27.16B N/A -34.32
GMAB Genmab AS

+0.56 (+1.59%)

USD22.96B 73.23 6.37
ARGX argenx NV ADR

+0.21 (+0.06%)

USD20.61B N/A -20.22

ETFs Containing ALXO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -40.48% 42% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.48% 42% F 28% F
Trailing 12 Months  
Capital Gain -80.52% 16% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.52% 16% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -17.16% 28% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.16% 28% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 51.16% 53% F 27% F
Risk Adjusted Return -33.54% 33% F 27% F
Market Capitalization 0.49B 70% C- 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 99% A+
Price/Book Ratio 1.21 67% D+ 68% D+
Price / Cash Flow Ratio -7.19 73% C 74% C
EV/EBITDA -1.05 51% F 64% D
Management Effectiveness  
Return on Equity -30.63% 78% C+ 31% F
Return on Invested Capital -21.08% 81% B- 32% F
Return on Assets -18.18% 72% C- 23% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.63 25% F 19% F
Short Percent 18.38% 8% F 10% F
Beta 2.21 9% F 7% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.